ITP
NBIX icon

Iron Triangle Partners’s Neurocrine Biosciences NBIX Stock Holding History

Iron Triangle Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-131,390
Closed -$18.4M – 39
2025
Q3 		$18.4M Buy
+131,390
New +$17.8M 2.62% 18
2025
Q2 		– Sell
-146,836
Closed -$16.2M – 34
2025
Q1 		$16.2M Sell
146,836
-171,359
-54% -$21.7M 2.56% 20
2024
Q4 		$43.4M Buy
+318,195
New +$39.4M 4.78% 8
2024
Q3 		– Sell
-200,000
Closed -$27.5M – 36
2024
Q2 		$27.5M Sell
200,000
-20,000
-9% -$2.74M 2.8% 18
2024
Q1 		$30.3M Buy
+220,000
New +$30M 3.11% 16
2023
Q1 		– Sell
-100,089
Closed -$12M – 32
2022
Q4 		$12M Sell
100,089
-255,512
-72% -$29.9M 2.14% 20
2022
Q3 		$37.8M Buy
355,601
+5,601
+2% +$568K 6.6% 3
2022
Q2 		$34.1M Buy
+350,000
New +$32.3M 4.42% 10

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Iron Triangle Partners's NBIX Position: Q4 2025 in Review

Iron Triangle Partners sold out of Neurocrine Biosciences (NBIX) in Q4 2025, closing a stake of 131,390 shares — an estimated $18.4M sold.

Iron Triangle Partners first reported a position in NBIX in Q2 2022 and held it in 8 quarters. The position peaked at $43.4M in Q4 2024. 732 funds tracked by Wall St. Rank hold NBIX as of Q4 2025.

  • Iron Triangle Partners reported no remaining Neurocrine Biosciences position as of Q4 2025 after selling out during the quarter.
  • Iron Triangle Partners sold 131,390 Neurocrine Biosciences shares in Q4 2025, an estimated $18.4M.
  • Iron Triangle Partners first reported a position in Neurocrine Biosciences in Q2 2022 and held it in 8 quarters.
  • Iron Triangle Partners's Neurocrine Biosciences position peaked at $43.4M in Q4 2024.
  • 732 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2025.

Based on Iron Triangle Partners's 13F filing for Q4 2025, filed 17 Feb 2026.